Merck Keytruda sales soar, but European application pulled

Published 7y ago

Merck & Co (MRK.N) on Friday said quarterly sales of its Keytruda cancer immunotherapy exceeded $1 billion for the first time, but it withdrew an application for European use of the drug in lung cancer, raising questions about future sales. More »